摘要
目的探讨FOLFOX6化疗方案对III、IV期结直肠癌的效果及对Tu M2-PK、FAS的影响。方法抽取2017年2月—2021年2月收治的33例III、IV期结直肠癌患者,根据治疗方案分为观察组(n=17)及对照组(n=16),对照组应用FOLFOX4方案治疗,观察组行FOLFOX6方案治疗,对两组化疗结果进行比较。结果观察组总有效率为64.71%,明显较对照组37.50%高,差异有统计学意义(P<0.05);治疗前,两组Tu M2-PK、FAS水平对比,差异无统计学意义(P>0.05),治疗后,观察组Tu M2-PK、FAS水平均较对照组低,差异有统计学意义(P<0.05);两组恶心呕吐、中性粒细胞减少、神经毒性、肝功能受损、腹泻等不良反应分级对比,差异无统计学意义(P>0.05);治疗前,两组IL-6、TGF-β水平对比,差异无统计学意义(P>0.05),治疗后,观察组上述炎性因子水平均较对照组低,差异有统计学意义(P<0.05);治疗前,两组生存质量评分差异无统计学意义(P>0.05),治疗后,观察组生存质量评分明显较对照组高,差异有统计学意义(P<0.05)。结论FOLFOX6化疗方案在III、IV期结直肠癌中应用价值较高,可提高近期疗效,降低血清Tu M2-PK、FAS水平,减轻炎症反应,提高患者生存质量,且不会明显增加恶心呕吐、腹泻等不良反应,有一定安全性,值得应用。
Objective To investigate the effect of FOLFOX6 chemotherapy on stage III and IV colorectal cancer and its influence on Tu M2-PK and FAS.Methods A sample of 33 patients with stage III and IV colorectal cancer admitted from February 2017 to February 2021 were divided into observation group(n=17)and control group(n=16)according to the treatment plan.The control group was treated with FOLFOX4 Plan treatment,the observation group was treated with FOLFOX6 regimen,and the chemotherapy results of the two groups were compared.Results The total effective rate in the observation group was 64.71%,which was significantly higher than 37.50%in the control group,the difference was statistically significant(P<0.05);before treatment,there was no statistically significant difference in Tu M2-PK and FAS levels between the two groups(P>0.05).Afterwards,the Tu M2-PK and FAS levels of the observation group were lower than those of the control group,the difference was statistically significant(P<0.05);the two groups were compared with the adverse reaction grades such as nausea and vomiting,neutropenia,neurotoxicity,liver damage,and diarrhea.There was no statistically significant difference(P>0.05);before treatment,there was no statistically significant difference in the levels of IL-6 and TGF-βbetween the two groups(P>0.05).After treatment,the levels of the above-mentioned inflammatory factors in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).Before treatment,the difference in quality of life scores between the two groups was not significant(P>0.05).After treatment,the quality of life scores in the observation group were significantly higher than those in the control group,the difference was statistically significant(P<0.05).Conclusion FOLFOX6 chemotherapy has a high application value in stage III and IV colorectal cancer.It can improve short-term efficacy,reduce serum Tu M2-PK and FAS levels,reduce inflammation,and improve the quality of life of patients and will n
作者
倪玲娜
霍丹
徐珍
刘永
徐建忠
蒋敏
NI Lingna;HUO Dan;XU Zhen;LIU Yong;XU Jianzhong;JIANG Min(Department of Oncology,Changzhou Cancer Hospital,Changzhou,Jiangsu Province,213032 China)
出处
《世界复合医学》
2021年第9期29-32,37,共5页
World Journal of Complex Medicine
基金
常州市科技计划(应用基础研究指导性)项目(NO.CJ20209022)。
